|1.||Bolton, Judy L: 4 articles (01/2009 - 02/2005)|
|2.||Thatcher, Gregory R J: 4 articles (01/2009 - 02/2005)|
|3.||Sporn, Michael B: 4 articles (10/2006 - 10/2002)|
|4.||Risingsong, Renee: 3 articles (10/2006 - 10/2002)|
|5.||Suh, Nanjoo: 3 articles (10/2006 - 10/2002)|
|6.||Williams, Charlotte R: 3 articles (10/2006 - 10/2002)|
|7.||Jordan, V Craig: 2 articles (05/2013 - 01/2006)|
|8.||Cummings, Steven R: 2 articles (07/2012 - 02/2011)|
|9.||Cox, David A: 2 articles (07/2012 - 01/2012)|
|10.||Muram, David: 2 articles (07/2012 - 01/2012)|
|1.||Breast Neoplasms (Breast Cancer)
04/01/2001 - "As predicted in preclinical testing, daily oral LY353381.HCl is safe, is well tolerated at all tested dose levels, and may be clinically beneficial in patients with extensively pretreated metastatic breast cancer. "
03/15/2003 - "Arzoxifene is effective in the treatment of TS and TR patients with advanced or metastatic breast cancer at the 20-mg and 50-mg dose levels. "
09/01/2003 - "Accordingly, arzoxifene 20 mg/day was selected for further study in patients with breast cancer."
03/15/2003 - "Accordingly, arzoxifene 20 mg/d was selected for further study in patients with breast cancer."
03/15/2003 - "This trial was a randomized, double-blind, phase II study of arzoxifene 20 mg (n = 55) and 50 mg (n = 57) in women with advanced or metastatic breast cancer. "
07/01/2012 - "There were 62 invasive breast cancers, 39 identified as invasive ER-positive (placebo 30, arzoxifene 9; HR 0.30, 95% CI 0.14-0.63, P=0.001) and 30 identified as invasive PR-positive (placebo 23, arzoxifene 7; HR 0.30, 95% CI 0.13-0.71, P=0.003). "
07/01/2012 - "A total of 75 breast cancers occurred 53 in the placebo group and 22 in the arzoxifene group (HR 0.41, 95% CI 0.25-0.68, P<0.001). "
08/15/2004 - "We performed a multi-institutional evaluation of arzoxifene in women with newly diagnosed ductal carcinoma in situ or T1/T2 invasive cancer. "
08/01/2003 - "Since this is an appealing combination for hormonal therapy of estrogen-related cancers, we initiated testing the potential of arzoxifene in women with treatment-refractory endometrial cancer. "
12/01/2001 - "Arzoxifene is a highly effective agent for prevention of mammary cancer induced in the rat by the carcinogen nitrosomethylurea and is significantly more potent than raloxifene in this regard. "
07/01/2012 - "The Generations trial, a multicenter, placebo-controlled, double-blind trial, compared arzoxifene 20 mg/day and placebo in 9,354 postmenopausal women with osteoporosis (N=5,252) or low bone mass (N=4,102). "
02/01/2011 - "In a randomized, blinded trial, women aged 60 to 85 years with osteoporosis, defined as a femoral neck or lumbar spine bone mineral density T-score of -2.5 or less or a vertebral fracture, and women with low bone mass, defined as a bone density T-score of -1.0 or less and above -2.5, were assigned to arzoxifene 20 mg or placebo daily. "
01/01/2012 - "Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass."
02/01/2011 - "After 3 years, the cumulative incidence of vertebral fractures in patients with osteoporosis was 2.3% lower in the arzoxifene group than in the placebo group, a 41% relative risk reduction [95% confidence interval (CI) 0.45-0.77, p < .001]. "
12/01/2002 - "These data suggest that arzoxifene may be a useful therapeutic agent for osteoporosis in postmenopausal women."
|4.||Endometrial Neoplasms (Endometrial Cancer)
08/01/2003 - "Arzoxifene as therapy for endometrial cancer."
01/01/2012 - "There were 13 adjudicated cases of endometrial cancer (placebo, 4 cases; arzoxifene, 9 cases: P = 0.165) and 6 cases of endometrial hyperplasia (placebo, 2 cases; arzoxifene, 4 cases). "
07/01/2003 - "A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer."
12/01/2001 - "Arzoxifene is devoid of the uterotrophic effects of tamoxifen, suggesting that, in contrast to tamoxifen, it is unlikely that the clinical use of arzoxifene will increase the risk of developing endometrial carcinoma."
10/01/2004 - "Preliminary data showed a high response rate and a favorable toxicity profile for arzoxifene in endometrial cancer, whereas letrozole could represent a new interesting therapeutic tool for endometrial cancer as well as for low-grade endometrial stromal sarcoma."
05/01/2010 - "Arzoxifene has been evaluated in phase 3 trials for postmenopausal osteoporosis and has been studied for the treatment of uterine malignancies but is no longer in clinical development. "
11/01/1998 - "LY353381 x HCl is a benzothiophene analog that is structurally related to raloxifene with potent selective estrogen receptor modulator activity in the ovariectomized rat model of postmenopausal osteoporosis. "
05/01/2009 - "A number of newer SERMs, including bazedoxifene, lasofoxifene, ospemifene, and arzoxifene, are currently in clinical development for the prevention and treatment of postmenopausal osteoporosis and for other indications. "
01/01/2009 - "Raloxifene and arzoxifene are benzothiophene selective estrogen receptor modulators (SERMs) of clinical use in postmenopausal osteoporosis and treatment of breast cancer and potentially in hormone replacement therapy. "
10/01/2009 - "Emerging therapies for postmenopausal osteoporosis include novel SERMs (bazedoxifene, lasofoxifene, ospemifene, arzoxifene) and denosumab. "
|2.||Selective Estrogen Receptor Modulators (SERM)
|6.||LY 353381 (LY353381)
|8.||tartrate salt cis- 1R- (4'- pyrrolidinoethoxyphenyl)- 2S- phenyl- 6- hydroxy- 1,2,3,4- tetrahydronaphthalene (Lasofoxifene)
|9.||Estrogen Receptor alpha
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)
|4.||Hormone Replacement Therapy (Therapy, Hormone Replacement)